Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

l minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary. A replay of the webcast will be archived on the Sunesis website for two weeks until March 25, 2008.

About Sunesis' Oncology Programs

Sunesis has built a portfolio of product candidates in oncology focused on inhibition of the cell-cycle and survival signaling. Our lead product candidate, SNS-595, is a novel naphthyridine analog, structurally related to quinolones, a class of compounds which has not been used previously for the treatment of cancer. SNS-595 is a specific DNA intercalator and topoisomerase II poison, causing replication-dependent site-selective double-strand DNA damage, irreversible G2 arrest and rapid apoptosis. A Phase 2 single agent clinical trial of SNS-595 in ovarian cancer and a Phase 1b clinical trial of SNS-595 combination with cytarabine in relapsed/refractory AML are both ongoing. SNS-032, a potent and selective inhibitor of CDKs 2, 7 and 9, is being evaluated in a Phase 1 clinical trial in patients with relapsed/refractory CLL or multiple myeloma. SNS-314, a potent and selective pan-Aurora kinase inhibitor, is being studied in a Phase 1 dose-escalating clinical trial in patients with advanced solid tumors. In addition, Sunesis is developing novel small molecule inhibitors of Raf kinase and other protein kinases in collaboration with Biogen Idec.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For further information o
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Calif. , Oct. 20, 2014 ... that the Company has signed a Notice of ... Regenerative Medicine (CIRM), effective October 1, 2014.  The ... Development payments and the release of additional grant ... CIRM grant award for clinical development of Asterias, ...
(Date:10/20/2014)... 20, 2014  GenVec, Inc. (NASDAQ: GNVC ) ... Ph.D., from its board of directors effective on October 24, ... and served as its chairman from June 2006 to November ... and Corporate Governance and Audit Committees of the board.  ... decade of dedicated service to GenVec, and its stockholders," said ...
(Date:10/20/2014)... Earle Martin , Chief ... that Ellen Teplitzky, an experienced attorney specializing in ... industry, has joined the firm as Director of ... practice. NDA Partners provides legal services, including ... to top law firms and their clients in ...
(Date:10/19/2014)... October 20, 2014 OCTOBER ... Meeting (ABIM). ABIM will take place ... information about ABIM 2014 is now available ... Delegates representing companies and organizations from all ... obtain information on the latest products and ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Zola P. Horovitz To Retire From GenVec Board 2NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2
... , ... Sinovac Biotech Ltd. ( SVA),a leading developer and provider ... (JV) agreement to establish Sinovac (Dalian) Vaccine,Technology Co., Ltd. ... human-use vaccines. Sinovac will contribute its expertise,and experience in ...
... This release is available in German . ... tags (Radio Frequency Identification) are increasingly finding their way into ... goods and identify them automatically by radio frequency. The appropriate ... label. Smart labels can be affixed to goods under production ...
... ... has agreed an AU$6.7 mil convertible note private placement with a U.S. institutional investor. ... advisor. , ... York (PRWEB) November 23, 2009 -- The independent New York investment bank KTA Capital, ...
Cached Biology Technology:Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 2Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 3Intelligence inside metal components 2KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2
(Date:10/15/2014)... non-traditional biophysics textbook and it describes how life functions ... discovery into biological systems and provides an understanding of ... about how our genes make proteins that control the ... in an organism. It quantifies the principles of life ... found on both large and small scales. The book ...
(Date:10/15/2014)... 44th Rosenstiel Award for Distinguished Work in Biomedical Science ... mechanisms of genomic instability and its implications for the ... alumnus to win the Rosenstiel Award; the first, Rod ... is the Charles A. Janeway Professor of Pediatrics and ... investigator at the Howard Hughes Medical Institute at Boston ...
(Date:10/14/2014)... have sequenced the house fly genome for the first ... from an insect that thrives in pathogen-rich dung piles ... in the journal Genome Biology , will increase ... how flies quickly adapt to resist insecticides, which could ... (Musca domestica) carry and transmit more than 100 human ...
Breaking Biology News(10 mins):New book about life as seen from physics 2Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2House fly genome reveals expanded immune system 2
... Stacia Sower, professor of biochemistry and director of ... University of New Hampshire, has received a $420,000 grant ... brain and pituitary hormones and receptors. With ... of NSF-funded research in the fields of hormonal genomics ...
... YORK (March 12, 2009) New software developed with ... researchers to rapidly identify individual animals by creating a ... The software, described in an issue of the journal ... origin of tigers from confiscated skins. The new software, ...
... (Mar. 12, 2009) Researchers from DaVinci Biosciences, Costa ... Ecuador, have determined that injecting a patient,s own bone ... column using multiple routes can be an effective treatment ... of life for SCI patients without serious adverse events. ...
Cached Biology News:Major NSF grant boosts UNH research on hormonal genomics 2Tracking tigers in 3-D 2Multiple route bone marrow stem cell injections show promise to treat spinal cord injury 2
... Supercoiled DNA Ladder is suitable ... 2 to 16 kb by ... bands can be visualized by ... also be detected on Southern ...
CREB-2 (H-290)...
... Dynabeads Tosylactivated (4.5 m). Hydrophobic naked ... coupling of antibodies for cell applications. Proteins ... covalent binding of primary amine groups (NH ... Coupling reactions can be performed at neutral ...
cysteine and glycine-rich protein 2,...
Biology Products: